Tempest Therapeutics: Tempest Reports Third Quarter 2024 Financial Results and Provides Business Update
Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree
Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...
Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...
TPST opened at $1.15 on Friday. Tempest Therapeutics has a 1-year low of $0.92 and a 1-year high of $7.32. The company has a current ratio of 2.17, a quick ratio of 2.17 and a debt-to-equity ratio ...
Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.
Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...
On Monday, Scotiabank reaffirmed its Sector Outperform rating and $13.00 stock price target for Tempest Therapeutics (NASDAQ:TPST), a biopharmaceutical company. The endorsement follows the ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Piper Sandler lowered the firm’s price target on Tempest Therapeutics (TPST) to $5 from $8 and keeps an Overweight rating on the shares following quarterly results. The FDA issued a “study may ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback